These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Evidence that endogenous somatostatin (SRIF) exerts a tonic inhibitory effect on the rat renin--angiotensin--aldosterone system.
    Author: Mazzocchi G, Malendowicz LK, Meneghelli V, Nussdorfer GG.
    Journal: In Vivo; 1992; 6(1):9-12. PubMed ID: 1352707.
    Abstract:
    The bolus ip. administration of a SRIF antagonist (SRIF-A) (60 nM/rat) significantly increased renin activity (PRA) and plasma aldosterone concentration (PAC) in rats, without affecting natremia, kalaemia and the blood levels of ACTH or corticosterone. SRIF-A also raised PAC in rats whose renin-angiotensin system had been pharmacologically interrupted by combined captopril/angiotensin-II infusion and in which PRA was very low. The ip. injection of an equimolar dose of SRIF completely reversed these effects of SRIF-A, but the administration of SRIF alone did not affect either PRA or PAC. Taken together, these data would suggest that, in the rat, endogenous SRIF exerts, under basal conditions, a two-fold maximum tonic inhibitory effect on both renin release by kidneys and aldosterone secretion by zona glomerulosa cells.
    [Abstract] [Full Text] [Related] [New Search]